The FDA pushed back the Prescription Drug User Fee Act action date for ruxolitinib cream (Opzelura) by three months to September 19, 2025. The extension will allow regulators time to review additional ...

A team led by the University of Exeter, and including researchers from King's College London, has been awarded a £3.3 million grant from the Medical ...

A team of researchers led by the University of Exeter have been awarded a £3.3 million grant by the Medical Research Council ...

Three months after the US Sofdra launch, prescriptions have exceeded Botanix Pharmaceuticals' expectations. What are they sweating on next?

The U.S. Food and Drug Administration (FDA) has announced a three-month extension for its review of the supplemental New Drug ...

Medically reviewed by Katlein Franca, MD Eczema is a chronic (long-lasting) inflammatory condition that causes rashes of scaly, irritated, itchy, dry skin. Affected areas can change color and harden.

Incyte (Nasdaq: INCY) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the ...

A significant interaction found between a genetic variant for atopic eczema and early-life exposure to pet dogs suggests that ...

Discover life-changing eczema treatments and remedies that provide real relief. From prescription breakthroughs to natural ...

The NHS has said that around 1 in 6 adults in the UK have low levels of Vitamin D - and this can lead to a variety of skin ...

One of the early signs of vitamin D deficiency is excessive sweating. It is often an overlooked sign. Excessive sweating, ...

PORTLAND, OR, UNITED STATES, June 18, 2025 /EINPresswire.com/ -- The global atopic dermatitis market is witnessing unprecedented growth, projected to expand from $5.3 billion in 2021 to $22.6 billion ...